Immunotherapy Use in Advanced Urothelial Carcinoma

EP. 1: Historic Perspective on Treatment of Bladder Cancer

March 16th 2017

EP. 2: Prognostic Subgroups in Advanced Bladder Cancer

March 16th 2017

EP. 3: PD-L1 Expression in Bladder Cancer

March 16th 2017

EP. 4: FDA Approval of Atezolizumab for Advanced Bladder Cancer

March 16th 2017

EP. 5: Bladder Cancer: Real-World Experience With Immunotherapy

March 16th 2017

EP. 6: Activity of Immunotherapy in the Frontline Setting

March 16th 2017

EP. 7: Chemotherapy Following Immunotherapy in Bladder Cancer

March 16th 2017

EP. 8: Update on Durvalumab for Metastatic Bladder Cancer

March 16th 2017

EP. 9: Immunotherapy Toxicity Management in Bladder Cancer

March 16th 2017

EP. 10: Combination Trials in Advanced Bladder Cancer

March 16th 2017

EP. 11: Bladder Cancer: Immunotherapy in the Perioperative Setting

March 16th 2017

EP. 12: BCG-Refractory Superficial Bladder Cancer

March 16th 2017

EP. 13: Bladder Cancer: Monoclonal Antibodies Under Investigation

March 16th 2017

EP. 14: The Future of Bladder Cancer Research

March 16th 2017